Venlafaxine ER for the Treatment of Pediatric Subjects With Depression
The DOI matches its Crossref record; 28 of the 29 references it cites were found in a registry or an index.
Abstract
Objective The safety, efficacy, and tolerability of venlafaxine extended release (ER) in subjects ages 7 to 17 years with major depressive disorder were evaluated in two multicenter, randomized, double-blind, placebo-controlled trials conducted between October 1997 and August 2001.Method Participants received venlafaxine ER (flexible dose, based on body weight; intent to treat, n = 169) or placebo (intent to treat, n = 165) for up to 8 weeks. The primary efficacy variable was the change from baseline in the Children's Depression Rating Scale-Revised score at week 8.Results There were no statistically significant differences between venlafaxine ER and placebo on the Children's Depression Rating Scale-Revised in either study. A post hoc age subgroup analysis of the pooled data showed greater improvement on the Children's Depression Rating Scale-Revised with venlafaxine ER than with placebo (-24.4 versus -19.9; p = .022) among adolescents (ages 12-17), but not among children (ages 7-11). The most common adverse events were anorexia and abdominal pain. Hostility and suicide-related events were more common in venlafaxine ER-treated participants than in placebo-treated participants. There were no completed suicides.Conclusions Venlafaxine ER may be effective in depressed adolescents. However, its safety and efficacy in pediatric patients has not been established. Prescribers should monitor for signs of suicidal ideation and hostility in pediatric patients taking venlafaxine ER.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Three adolescent and young adult RCT studies found antidepressants reduced suicidal ideation,(62, 64, 65) one did not,(85) and none found a reduction in suicide behavior.”
From Improving Suicide Prevention Through Evidence-Based Strategies: A Systematic Review (2021) · cites this paper as [85]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 1×
“Secondary outcome measures were the 21-Item Hamilton Rating Scale for Depression (HAM-D)21 (Hamilton, 1960), MontgomeryÅsberg Depression Rating Scale (MADRS; Montgomery and Åsberg, 1979), and CGI-S and CGI-Improvement scales.”
MethodA new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
KAUFMAN, J., BIRMAHER, B., BRENT, D., RAO, U., FLYNN, C., MORECI, P., WILLIAMSON, D., & RYAN, N. (1997) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199707000-00021 · Cited by 10,148
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
Hu, R. J. (2003) · Encyclopedia of the Neurological Sciences · doi:10.1016/b0-12-226870-9/01070-4 · Cited by 9,117
(1976) · Medical Entomology and Zoology · Cited by 8,899
Suicidality in Pediatric Patients Treated With Antidepressant Drugs
Hammad, T. A., Laughren, T., & Racoosin, J. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.3.332 · Cited by 1,054
Emslie, G. J. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830230069010 · Cited by 985
Self-citationKELLER, M. B., RYAN, N. D., STROBER, M., KLEIN, R. G., KUTCHER, S. P., BIRMAHER, B., HAGINO, O. R., KOPLEWICZ, H., CARLSON, G. A., CLARKE, G. N., et al. (2001) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200107000-00010 · Cited by 641 · cited 3×
“, 1997b, 1998, 2002), paroxetine (Braconnier et al., 2003; Keller et al., 2001), sertraline (Wagner et al.”
ResultInfluentialSelf-citationEMSLIE, G. J., HEILIGENSTEIN, J. H., WAGNER, K. D., HOOG, S. L., ERNEST, D. E., BROWN, E., NILSSON, M., & JACOBSON, J. G. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200210000-00010 · Cited by 581
Self-citationUnipolar Depression in Adolescents: Clinical Outcome in Adulthood
RAO, U., RYAN, N. D., BIRMAHER, B., DAHL, R. E., WILLIAMSON, D. E., KAUFMAN, J., RAO, R., & NELSON, B. (1995) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199505000-00009 · Cited by 514
Research works printed but not linked: 3
- DeVane, 1996, Serotonin selective reuptake inhibitors in child and adolescent psychopharmacology: a review of published experience, J Clin Psychiatry, 57, 55
- Kessler, 1998, Epidemiology of DSM-III-R major depression and minor depression among adolescents and young adults in the National Comorbidity Survey, Depress Anxiety, 7, 3, 10.1002/(SICI)1520-6394(1998)7:1<3::AID-DA2>3.0.CO;2-F · DOI · Paper page
- Sood, 2004, SSRIs in children and adolescents: where do we stand?, Curr Psychiatry, 3, 83
Cited by
Bridge, J. A., Iyengar, S., Salary, C. B., Barbe, R. P., Birmaher, B., Pincus, H. A., Ren, L., & Brent, D. A. (2007) · JAMA · doi:10.1001/jama.297.15.1683 · Cited by 1,086
Birmaher, B., & Brent, D. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e318145ae1c · Cited by 1,056
“Secondary analysis of the venlafaxine trials showed an age effect, with these medications being better than placebo for depressed adolescents, but not depressed children (Emslie et al., 2007 [rct]); however, children were treated with low venlafaxine doses.”
BackgroundCipriani, A., Zhou, X., Del Giovane, C., Hetrick, S. E., Qin, B., Whittington, C., Coghill, D., Zhang, Y., Hazell, P., Leucht, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30385-3 · Cited by 734
Brent, D., Emslie, G., Clarke, G., Wagner, K. D., Asarnow, J. R., Keller, M., Vitiello, B., Ritz, L., Iyengar, S., Abebe, K., et al. (2008) · JAMA · doi:10.1001/jama.299.8.901 · Cited by 700
“Income, median (range), thousands $ 60 (8-500) 62 (0-250) .”
Self-citationImproving Suicide Prevention Through Evidence-Based Strategies: A Systematic Review
Mann, J. J., Michel, C. A., & Auerbach, R. P. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20060864 · Cited by 655
Zuckerbrot, R. A., Cheung, A., Jensen, P. S., Stein, R. E. K., Laraque, D., GLAD-PC STEERING GROUP, Levitt, A., Birmaher, B., Campo, J., Clarke, G., et al. (2018) · Pediatrics · doi:10.1542/peds.2017-4081 · Cited by 446
Self-citationLocher, C., Koechlin, H., Zion, S. R., Werner, C., Pine, D. S., Kirsch, I., Kessler, R. C., & Kossowsky, J. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.2432 · Cited by 360
Solmi, M., Fornaro, M., Ostinelli, E. G., Zangani, C., Croatto, G., Monaco, F., Krinitski, D., Fusar‐Poli, P., & Correll, C. U. (2020) · World Psychiatry · doi:10.1002/wps.20765 · Cited by 324
Newer generation antidepressants for depressive disorders in children and adolescents
Hetrick, S. E., McKenzie, J. E., Cox, G. R., Simmons, M. B., & Merry, S. N. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004851.pub3 · Cited by 291
Interventions for self-harm in children and adolescents
Hawton, K., Witt, K. G., Taylor Salisbury, T. L., Arensman, E., Gunnell, D., Townsend, E., van Heeringen, K., & Hazell, P. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012013 · Cited by 261
Bridge, J. A., Birmaher, B., Iyengar, S., Barbe, R. P., & Brent, D. A. (2009) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2008.08020247 · Cited by 256
“…2004 268 12.3 52 71 — Berard et al. 2006 (28) Paroxetine, 20–40 mg 1998 286 15.6 66 68 70 Emslie et al. 2006 (29) Paroxetine, 10–50 mg 2001 206 12.0 47 79 53 Emslie et al. 2007 (30)b Venlafaxine, 37.5–225 mg 2001 367 12.2 46 78 86 Emslie et al. 2002 (31)b,h Nefazodone, 100–600 mg 2001 206 14.7 59…”
InfluentialMELTON, T. H., CROARKIN, P. E., STRAWN, J. R., & MCCLINTOCK, S. M. (2016) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000132 · Cited by 196
Rendleman, R., & Walkup, J. T. (2012) · Swaiman's Pediatric Neurology · doi:10.1016/b978-1-4377-0435-8.00049-4 · Cited by 196
New generation antidepressants for depression in children and adolescents: a network meta-analysis
Hetrick, S. E., McKenzie, J. E., Bailey, A. P., Sharma, V., Moller, C. I., Badcock, P. B., Cox, G., Merry, S., & Meader, N. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013674.pub2 · Cited by 269
HUGHES, C. W., EMSLIE, G. J., CRISMON, M. L., POSNER, K., BIRMAHER, B., RYAN, N., JENSEN, P., CURRY, J., VITIELLO, B., LOPEZ, M., et al. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31804a859b · Cited by 168
“Two acute venlafaxine trials (Emslie et al., 2007) and two acute mirtazapine trials in children and adolescents with MDD have been negative (Cheung et al., 2005, although the pooled data from the venlafaxine trials indicate some efficacy for adolescents, but not for children.”
BackgroundSelf-citationEfficacy of antidepressants in juvenile depression: meta-analysis
Tsapakis, E. M., Soldani, F., Tondo, L., & Baldessarini, R. J. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.106.031088 · Cited by 150
Annual Research Review: Defining and treating pediatric treatment‐resistant depression
Dwyer, J. B., Stringaris, A., Brent, D. A., & Bloch, M. H. (2020) · Journal of Child Psychology and Psychiatry · doi:10.1111/jcpp.13202 · Cited by 148
Walkup, J. T. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.16091059 · Cited by 112
Depressive disorders in childhood and adolescence
Brent, D., & Maalouf, F. (2015) · Rutter's Child and Adolescent Psychiatry · doi:10.1002/9781118381953.ch63 · Cited by 94
The effect of antidepressants and antipsychotics on weight gain in children and adolescents
Reekie, J., Hosking, S. P. M., Prakash, C., Kao, K. ‐., Juonala, M., & Sabin, M. A. (2015) · Obesity Reviews · doi:10.1111/obr.12284 · Cited by 72
“Serotonin and norepinephrine reuptake inhibitor medication versus placebo Two SNRI trials both reported weight loss in the medication groups when compared with placebo (34,35) (Table 4).”
MethodResultCohen, D., Deniau, E., Maturana, A., Tanguy, M., Bodeau, N., Labelle, R. J., Breton, J., & Guilé, J.-M. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002632 · Cited by 74
Sleep complaints among adolescent outpatients with major depressive disorder
Urrila, A. S., Karlsson, L., Kiviruusu, O. H., Pelkonen, M. U. I., Strandholm, T., & MARTTUNEN, M. J. (2012) · Sleep Medicine · doi:10.1016/j.sleep.2012.04.012 · Cited by 80
Efficacy and safety of antidepressant drug treatment in children and adolescents
Henry, A., Kisicki, M. D., & Varley, C. (2011) · Molecular Psychiatry · doi:10.1038/mp.2011.150 · Cited by 64
Child and Adolescent Depression Intervention Overview: What Works, for Whom and How Well?
Maalouf, F. T., & Brent, D. A. (2012) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2012.01.001 · Cited by 72
Meister, R., Abbas, M., Antel, J., Peters, T., Pan, Y., Bingel, U., Nestoriuc, Y., & Hebebrand, J. (2018) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-018-1244-7 · Cited by 55
Rutherford, B. R., Sneed, J. R., Tandler, J. M., Rindskopf, D., Peterson, B. S., & Roose, S. P. (2011) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2011.04.004 · Cited by 51
Adolescent depression: an update and guide to clinical decision making.
Cook, M. N., Peterson, J., & Sheldon, C. (2009) · PubMed Central · Cited by 79
Weihs, K. L., Murphy, W., Abbas, R., Chiles, D., England, R. D., Ramaker, S., & Wajsbrot, D. (2017) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2017.0100 · Cited by 52
“…medications have been assessed for efficacy for treating MDD in pediatric populations, including selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs) (Emslie et al. 1997, 2002, 2007, 2009, 2014; Wagner et al. 2003, 2004; Atkinson et al. 2014).”
BackgroundResultUrrila, A. S., Hakkarainen, A., Castaneda, A., Paunio, T., Marttunen, M., & Lundbom, N. (2017) · Neuropsychobiology · doi:10.1159/000478861 · Cited by 43
Pharmacotherapy of major depressive disorder in adolescents
Masi, G., Liboni, F., & Brovedani, P. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903527226 · Cited by 42
“Regarding venlafaxine, two placebo-controlled trials were unable to find a statistically significant difference from placebo [43].”
BackgroundSiddique, J., Reiter, J. P., Brincks, A. M., Gibbons, R. D., Crespi, C. M., & Brown, C. H. (2015) · Statistics in Medicine · doi:10.1002/sim.6562 · Cited by 42
“order to estimate the association between the two depression measures, data from two additional placebocontrolled adolescent depression trials were obtained, which used a different medication (venlafaxine), but included summary scores for both the CDRS and the HDRS on every participant [16].”
Rohden, A. I., Benchaya, M. C., Camargo, R. S., Moreira, T. D. C., Barros, H. M. T., & Ferigolo, M. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.03.017 · Cited by 35
Atkinson, S. D., Lubaczewski, S. L., Ramaker, S., England, R. D., Wajsbrot, D., Abbas, R., & Findling, R. L. (2017) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2017.0099 · Cited by 34
“2014), and venlafaxine (Emslie et al. 2007) for pediatric MDD, and may have influenced study outcomes.”
BackgroundResultInfluentialSelf-citationDurgam, S., Chen, C., Migliore, R., Prakash, C., Edwards, J. G., & Findling, R. L. (2018) · Pediatric Drugs · doi:10.1007/s40272-018-0290-4 · Cited by 41
“Evidence for SNRIs in child and adolescent depression is lacking, with some differences for venlafaxine versus placebo reported in two trials [36] and two failed trials reported for duloxetine [37, 38].”
ResultSelf-citationTime-Lag Bias in Trials of Pediatric Antidepressants: A Systematic Review and Meta-Analysis
Reyes, M. M., Panza, K. E., Martin, A., & Bloch, M. H. (2010) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2010.10.008 · Cited by 35
Prescriber's Guide – Children and Adolescents: Stahl's Essential Psychopharmacology
Stahl, S. M. (2018) · Cambridge University Press eBooks · doi:10.1017/9781108561402 · Cited by 35
Improving Suicide Prevention Through Evidence-Based Strategies: A Systematic Review
Mann, J. J., Michel, C. A., & Auerbach, R. P. (2023) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.23021004 · Cited by 38
“Three randomized controlled trials in adolescents and young adults found that antidepressants reduced suicidal ideation (62, 64, 65), one study did not (85), and none found a reduction in suicidal behavior.”
Primary Pediatric Care Psychopharmacology: Focus on Medications for ADHD, Depression, and Anxiety
Strawn, J. R., Dobson, E. T., & Giles, L. L. (2016) · Current problems in pediatric and adolescent health care · doi:10.1016/j.cppeds.2016.11.008 · Cited by 43
Feeney, A., Hock, R. S., D, M. F. M., Ortiz, J. M. H., Iovieno, N., & Papakostas, G. I. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.02.074 · Cited by 40
Generalizability of Clinical Trial Results for Adolescent Major Depressive Disorder
Blanco, C., Hoertel, N., Franco, S., Olfson, M., He, J.-P., López, S., González-Pinto, A., Limosin, F., & Merikangas, K. R. (2017) · Pediatrics · doi:10.1542/peds.2016-1701 · Cited by 29
Ma, D., Zhang, Z., Zhang, X., & Li, L. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.860020 · Cited by 41
SSRIs and SNRIs: A review of the Discontinuation Syndrome in Children and Adolescents.
Hosenbocus, S., & Chahal, R. (2011) · PubMed Central · Cited by 52
Developmental Epidemiology of Depressive Disorders
Goldman, S. (2012) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2011.12.002 · Cited by 33
Xu, Y., Bai, S. J., Lan, X. H., Qin, B., Huang, T., & Xie, P. (2016) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20164806 · Cited by 24
Merikanto, I., Partonen, T., Paunio, T., Castaneda, A. E., MARTTUNEN, M. J., & Urrila, A. S. (2017) · Chronobiology International · doi:10.1080/07420528.2017.1332072 · Cited by 27
“…(BDI-21) (Beck et al., 1961), and the Hamilton Depression Rating Scale (HDRS) (Hamilton, 1960), both of which have been successfully applied to adolescent samples (Brooks & Kutcher, 2001; Clarke et al., 2005; Emslie et al., 2007; Marton et al., 1991; Mufson et al., 2004; Urrila et al., 2012).”
MethodEfficacy and suicidal risk for antidepressants in paediatric and adolescent patients
Julious, S. (2013) · Statistical Methods in Medical Research · doi:10.1177/0962280211432210 · Cited by 23
Pharmacotherapy in depressed children and adolescents
Taurines, R., Gerlach, M., Warnke, A., Thome, J., & Wewetzer, C. (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.600295 · Cited by 26
“In children, no benefi t in comparison to placebo could be reported; however, a positive effect in adolescents was observed (Mandoki et al. 1997; Courtney 2004; Emslie et al. 2007; Bailly 2008).”
BackgroundChoe, C. J., Emslie, G. J., & Mayes, T. L. (2012) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2012.07.002 · Cited by 26
Self-citationControversies in the Pharmacotherapy of Adolescent Depression
Masi, G. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220526150153 · Cited by 25
Purper‐Ouakil, D., Cohen, D., & Flament, M. F. (2011) · Neuropsychiatrie de l Enfance et de l Adolescence · doi:10.1016/j.neurenf.2011.03.001 · Cited by 22
“[42] Emslie GJ, Findling RL, Yeung PP, Kunz NR, Li Y, Venlafaxine ER.”
BackgroundLi, Y., Huang, J., He, Y., Yang, J., Lv, Y., Liu, H., Liang, L., Li, H., Zheng, Q., & Li, L. (2019) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2019.0022 · Cited by 17
“…of 40 groups were included for analysis, of which 22 groups were given antidepressants ( N = 2500) and 18 groups received a placebo ( N = 1865) (Emslie et al. 1997, 2002, 2006, 2007, 2009, 2014; Keller et al. 2001; Organon Pharmaceuricals USA, Inc. 2001; Wagner et al. 2003, 2004, 2006; March…”
Self-citationBenefits and risks of using antidepressants in children and adolescents
Bailly, D. (2008) · Expert Opinion on Drug Safety · doi:10.1517/14740338.7.1.9 · Cited by 18
“02), but not among children aged 7 – 11 years [19] .”
BackgroundResultGentile, S. (2010) · Reviews on Recent Clinical Trials · doi:10.2174/157488710790820517 · Cited by 17
Courtney, D., Watson, P., Chan, B. W. C., BENNETT, K. J., Krause, K. R., Offringa, M., Butcher, N. J., Monga, S., Neprily, K., Zentner, T., et al. (2021) · Depression and Anxiety · doi:10.1002/da.23200 · Cited by 17
Fekete, S., Scherf‐Clavel, M., Unterecker, S., Egberts, K. M., Gerlach, M., Romanos, M., & Kittel‐Schneider, S. (2020) · Pharmacopsychiatry · doi:10.1055/a-1302-8108 · Cited by 15
“In contrast, in children and adolescents, daily doses of VEN [29] and RIS [30, 31] were higher, and, accordingly, trough serum concentrations of the AM of RIS also were higher in our sample compared to previously reported studies [30, 31]; however, children/adolescents receiving RIS were older in our sample and the do…”
ResultWhen do you Prescribe Antidepressants to Depressed Children?
Soutullo, C. A., & Quintana, A. F. (2013) · Current Psychiatry Reports · doi:10.1007/s11920-013-0366-3 · Cited by 15
Advances in the prevalence and treatment of depression for adolescents: a review
Yin, C., Xu, M., & Zong, Z. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1574574 · Cited by 15
Psychopharmacology of Depression in Children and Adolescents
Smiga, S., & Elliott, G. R. (2011) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2010.11.007 · Cited by 16
Psychopharmaka im Kindes- und Jugendalter
Trott, G. (2008) · Springer eBooks · doi:10.1007/978-3-540-68748-1_57 · Cited by 12
Türkmen, C., Machunze, N., Lee, A. M., Bougelet, E., Ludin, N. M., de Cates, A. N., Vollstädt‐Klein, S., Bach, P., Kiefer, F., Andreas, J. B., et al. (2025) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2025.01.006 · Cited by 13
Self-citationCarandang, C. G., Santor, D. A., Gardner, D. M., CARREY, N. J., & Kutcher, S. (2007) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/chi.0b013e31802f5f54 · Cited by 10
Pharmacotherapy and psychotherapy of pediatric depression
Maalouf, F. T., & Brent, D. A. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.496451 · Cited by 11
“Venlafaxine has been as efficacious as SSRI in the treatment of resistant depression, and may be efficacious in the acute treatment of depressed adolescents only [34,39].”
BackgroundResultEscitalopram for the treatment of major depressive disorder in youth
Ahn, J., & Patkar, A. A. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.604632 · Cited by 11
“There have been two multicenter, double-blind, placebocontrolled trials of venlafaxine extended release (ER) for the treatment of major depression in 165 and 201 children and adolescents, aged 7 -- 17 years [24].”
BackgroundEvidence-based treatment of adolescent major depression
Dubicka, B., & Wilkinson, P. O. (2007) · Evidence-Based Mental Health · doi:10.1136/ebmh.10.4.100 · Cited by 11
Steyn, S. F., Harvey, B. H., & Brink, C. B. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.14757 · Cited by 9
Yoshimatsu, H., Imaeda, T., Higa, S., & Nomoto, K. (2023) · Health Science Reports · doi:10.1002/hsr2.1512 · Cited by 8
“Further details of these clinical trials including eligibility criteria and study population are described in the previous reports.(6,7) The clinical studies were complied with the Declaration of Helsinki and Good Clinical Practice.”
MethodKoslow, S. H., Ruiz, P., & Nemeroff, C. B. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781139519502.028 · Cited by 8
Treatment of Depression in Children and Adolescents
Bujoreanu, S. I., Benhayon, D., & Szigethy, E. (2011) · Pediatric Annals · doi:10.3928/00904481-20111007-05 · Cited by 8
Inappropriate Data and Measures Lead to Questionable Conclusions
Spielmans, G. I., Jureidini, J. N., Healy, D. T., & Purssey, R. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.747 · Cited by 8
Boldrini, M., & Mann, J. J. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85654-6.00039-3 · Cited by 9
Psychiatric Diseases in Children and Adolescents
Cardwell, G. S., Findling, R. L., & Robb, A. S. (2019) · Handbook of experimental pharmacology · doi:10.1007/164_2019_262 · Cited by 7
Self-citationNasir, M., Li, F., Courley, S., Olten, B., & Bloch, M. H. (2021) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2021.0030 · Cited by 8
“Thirty trials involving 2911 participants receiving placebo contributed to this outcome (Riddle et al. 1992, 2001; Emslie et al. 1997, 2002, 2006, 2007, 2009, 2014; March et al. 1998, 2004, 2007; Geller et al. 2001, 2004; Keller et al. 2001; Rynn et al. 2001, 2007; Walkup et al. 2001, 2008;…”
How do we Safely Treat Depression in Children, Adolescents and Young Adults?
Jureidini, J. N. (2009) · Drug Safety · doi:10.2165/00002018-200932040-00002 · Cited by 6
Radecki, D. T., Robieson, W., Gopalkrishnan, M., Greenberg, E. F., & AZIZ, M. A. (2024) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2023.0080 · Cited by 6
Findling, R. L., Groark, J., Tourian, K. A., Ramaker, S., Chiles, D., Yang, L., & Nichols, A. I. (2016) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2016.0009 · Cited by 7
“…among the most common TEAEs reported in pediatric clinical trials of the SNRI duloxetine (Atkinson et al. 2014; Emslie et al. 2014) and venlafaxine (Emslie et al. 2007), and the selective serotonin reuptake inhibitor (SSRI) fluoxetine (March et al. 2004; Emslie et al. 2006; Emslie et al. 2014).”
Self-citationRao, Y., Yang, R., Zhao, J., & Cao, Q. (2022) · Journal of Zhejiang University (Medical Sciences) · doi:10.3724/zdxbyxb-2022-0145 · Cited by 11
Frölich, J., Lehmkuhl, G., & Döpfner, M. (2010) · Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie · doi:10.1024/1422-4917.a000002 · Cited by 5
Geller, J. A., & Whitney, E. (2024) · Current Psychiatry Reports · doi:10.1007/s11920-024-01577-2 · Cited by 6
The Treatment of Pediatric Suicidal Behavior
Burke, T. A., Buchanan, J., Amira, L., Yershova, K. V., & Posner, K. (2014) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-014-0008-3 · Cited by 6
contact, A. T. O. O. T. I., plan, T. C. S. C. W. T. P. A. P. T. B. O. T. C. R. T. W. B. P. T. C. R. T. A. C. R. I. D. B. L. T. V. B. S. E. S. H. M. C. A. R. R. P. W. E. I. A. T. T., plan, T. S., providers, A. P. T. G. O. T. T. C. S. E. T. S. O. V. R. I. W. B. C. T. T. P. T. C. S. R. P. T. C. W. M., treatment, O. M. H. P. I. I. T., & use., A. A. S. P. C. S. P. A. M. F. P. T. C. C. A. D. I. F. A. H.-R. B. S. A. S. T. O. S. (2008) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/foc.6.3.foc379 · Cited by 5
Depression in Children and Adolescents: Optimizing Treatment
Tao, R., Moore, J., Mayes, T. L., & Emslie, G. J. (2007) · Pediatric Health · doi:10.2217/17455111.1.2.217 · Cited by 3
“analyzed the pooled data from the two identical trials and found that, for adolescents only but not children, venlafaxine is more efficacious than placebo [45].”
MethodSelf-citationOkubo, R., Matsui, K., & Narukawa, M. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01273-8 · Cited by 4
Medikamentell behandling av depresjon hos barn og ungdom
Grøholt, B. (2011) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.10.0282 · Cited by 4
Pharmacotherapy of child and adolescent depression: a review
Tutkunkardaş, M. D., & Kılınçaslan, A. (2011) · Journal of Mood Disorders · Cited by 2
Gordon, M., & Melvin, G. A. (2014) · Journal of Paediatrics and Child Health · doi:10.1111/jpc.12517 · Cited by 2
Brent, D. A. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139175869.011 · Cited by 2
Treatment Response in Behaviour Disorders in Rett Syndrome
Martínez, A. R., Turón, M., Póo, L. C., Sole, E., Armstrong, J., & Pineda, M. (2013) · Journal of Behavioral and Brain Science · doi:10.4236/jbbs.2013.32023 · Cited by 2
“To conclude, serotonin reuptake might be impaired in RTT, as experimental studies have demonstrated, but the clinical effects of venlafaxine (SNRI) and citalopram (SSRI) in RTT patients were not clinically relevant in this small group.”
BackgroundInfluentialAntidepressant Treatment of Pediatric Depression
Vela, R. M., Glod, C. A., Rivinus, T. M., & Johnson, R. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-435-7_9 · Cited by 2
Mood Disorders in Children and Adolescents
Cullen, K. R., & Bortnova, A. (2016) · Springer eBooks · doi:10.1007/978-1-4939-2528-5_19 · Cited by 4
Taurines, R., Gerlach, M., & Warnke, A. (2016) · Springer eBooks · doi:10.1007/978-3-662-48624-5_5 · Cited by 3
Taurines, R., Warnke, A., Greenhill, L. L., & Gerlach, M. (2014) · Springer eBooks · doi:10.1007/978-3-7091-1501-5_4 · Cited by 2
Yoshimatsu, H., Imaeda, T., Yoshiyama, T., Higa, S., & Nomoto, K. (2022) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2021.0141 · Cited by 3
“The data from four clinical studies of venlafaxine and sertraline in children and adolescents with major depression (Wagner et al. 2003; Emslie et al. 2007) were used in this investigation.”
Psychopharmacology for Pediatric Depressive Disorders
Rengasamy, M. L., Shalev, A., & Birmaher, B. B. (2024) · Springer eBooks · doi:10.1007/978-3-031-57472-6_16 · Cited by 2
Treatment of Depression in Children and Adolescents
Kızıl, N., & Uyar, B. (2024) · doi:10.69860/nobel.9786053359456.9 · Cited by 2
Chapter 60. Treatment of Child and Adolescent Disorders
Wagner, K., & Pliszka, S. R. (2024) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9781615375523.as60 · Cited by 1
Krivosova, M., Žideková, N., Kubisova, Z., Bělohlávek, T., Kucianová, V., Nosáľ, S., & Kertys, M. (2026) · Journal of Analytical Toxicology · doi:10.1093/jat/bkag080 · Cited by 1
Antidepressant drug treatment in Child and adolescent Psychiatry
Cardy, R. E., Dhaliwal, S. S., & Reddy, P. S. (2017) · Madridge Journal of Internal and Emergency Medicine · doi:10.18689/mjiem-1000106 · Cited by 2
“Extended-release venlafaxine [42] even pediatric patients who are treated successfully during an acute episode may need longer-term treatment.”
BackgroundTratamiento multimodal de niños y adolescentes con depresión
Ulloa, R. E., de la Peña, F. R., & Nogales-Imaca, I. A. (2011) · Redalyc (Universidad Autónoma del Estado de México) · Cited by 1
Venlafaxine Extended Release in Pediatric Anxiety and Depression
Miller, L., & Riddle, M. A. (2008) · Pediatric Health · doi:10.2217/17455111.2.3.279 · Cited by 1
Blass, B. E. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-411508-8.00008-6 · Cited by 2
Metadata
- Authors
- EMSLIE, G. J., FINDLING, R. L., YEUNG, P. P., KUNZ, N. R., & LI, Y.
- Affiliations
- Yale University (US)
- Corresponding author
- EMSLIE, GRAHAM J.
- Venue
- Journal of the American Academy of Child & Adolescent Psychiatry
- Publisher
- Elsevier BV
- Published
- 2007-04
- Volume
- 46
- Issue
- 4
- Pages
- 479-488
- ISSN
- 0890-8567 (ISSN-L)
- OpenAlex
- W1520036360
- Cited by
- 135
- References
- 29
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 10 · 2023: 5 · 2022: 7 · 2021: 6 · 2020: 4 · 2019: 3 · 2018: 5 · 2017: 9 · 2016: 9 · 2015: 5 · 2014: 8 · 2013: 8 · 2012: 11
- FWCI
- 6.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- Journal of the American Academy of Child & Adolescent Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Child and Adolescent Psychosocial and Emotional Development
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Keywords
- venlafaxine extended release, childhood depression, major depressive disorder, adolescents, Children's Depression Rating Scale-Revised, antidepressant efficacy, adverse events, anorexia, hostility, suicidal ideation, suicide risk, drug safety
- MeSH terms
- Venlafaxine Hydrochloride, Adolescent, Algorithms, Child, Cyclohexanols, Delayed-Action Preparations, Major Depressive Disorder, Depressive Disorder, Major, Double-Blind Method, Female, Humans, Male, Placebos, Suicide, Attempted, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Endpoint Determination
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.